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Summary Despite inadequacy in preventing vivax malaria after travel, suppressive chemo-
prophylaxis has dominated travel medicine strategy since the advent of chloroquine in 1946.
The lethal threat of falciparum malaria versus the perceived benign consequence of vivax ma-
laria underpins this strategic posture. Recent evidence demonstrating vivax malaria as often
pernicious should prompt reconsideration of that posture. Causal prophylaxis kills early devel-
oping forms of plasmodia in the liver, thus preventing attacks of falciparum and vivax malaria
during travel and delayed onset vivax malaria following travel. Primaquine is the only available
drug for this application, and has good evidence of safety, tolerability and efficacy in non-
pregnant, G6PD-normal travelers. The primaquine label, however, carries no such indication.
Risk of pernicious vivax malaria from all across the endemic regions of the globe, including
much of sub-Saharan Africa, should raise consideration of daily primaquine during travel as
the preferred front-line option for chemoprophylaxis against malaria in travelers.
ª 2013 Published by Elsevier Ltd.
Acute pernicious vivax malaria
Malariologists, along with the workers in public health,
science, and medicine who engage the malaria problem,
have long accepted the notion that vivax malaria is almost
always harmless. Consider the opening to the article, “The
Other Malaria”, that appeared in the May 26th 2011 edition
of The Economist, “‘When is a disease not a disease?’
sounds like a childhood riddle. One answer, though might
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be, ‘when it is vivax malaria.’” It goes on to explain, “Vivax
debilitates but it rarely kills.” This view accurately reflects
dominant expert opinion, but recent evidence from
endemic zones shows approximately equal risk of severe or
fatal illness with a diagnosis of Plasmodium vivax or Plas-
modium falciparum among patients hospitalized with a
primary diagnosis of malaria.1 Further, a comprehensive
review of the historic evidence underpinning benign iden-
tity for P. vivax revealed nullifying weaknesses.1 Vivax
malaria is certainly not inherently benign as long perceived,
but it possesses the capacity to become pernicious. The
broad perception of benign consequence may be the most
dangerous aspect of vivax malaria e its threat to human life
is not acknowledged, understood, or addressed.
The estimated population at risk and the burden of
disease with infection by P. vivax number several billion
and a hundred million or more, respectively, and span the
endemic world from the Korean peninsula to northern
Argentina (Fig. 1).2,3 This species exhibits far less respon-
siveness to standard methods of control and prevention
than P. falciparum, principally because the available che-
motherapeutics are not fit for purpose against endemic
vivax malaria (Fig. 2, from4). The benign identity assigned
to P. vivax effectively arrested research on this infection
sixty years ago (Fig. 3). Almost no research on therapies
that prevent relapse has been done since the development
of primaquine in American prisoner volunteers during and
immediately after World War II.5 This neglect bears directly
on questions of central importance to malaria as a problem
of travel medicine.
Traveler beware
As Fig. 1 illustrates, endemic vivax malaria occurs across
much of the globe. Providers of travel medicine services
obviously should carefully consider the threat to their pa-
tients posed by P. vivax. The decision on chemoprophylaxis
versus personal protection is complex and based on often-
inadequate data for rational assessments of real risk of
exposure. This is also true for vivax malaria, but the false
aegis of benign consequence versus deadly falciparum
malaria may weigh inappropriately upon that decision-
making process. In fact, vivax malaria not only carries risk
of serious illness and death, but it also threatens in ways P.
falciparum does not: 1) it is widely perceived as clinically
inconsequential; 2) it may be much more prevalent than
blood surveys like those underpinning Fig. 1 suggest; 3) the
bulk of its threatening biomass in patients may occur
beyond vascular sinuses and convenient assessment; 4)
standard therapy for radical cure, chloroquine and prima-
quine, has been in continuous use since 1952 and suffers a
number of serious pitfalls; 5) no alternative radical cure
except quinine and primaquine has proven safety and effi-
cacy; and 6) standard suppressive chemoprophylaxis does
not prevent seeding of the liver with hypnozoites and risk of
multiple relapses in the weeks and months following travel.
In short, risk of infection by P. vivax is widespread, poses an
inherent and insidious clinical threat, and it is notoriously
difficult to prevent and treat.
Travel medicine provider beware
A rational and practical strategy for avoiding acute vivax
malaria would of course be useful to providers of travel
medicine services and their patients. In considering chemo-
prophylactic strategy, the greater biological complexity of P.
vivax compared to P. falciparum imposes important technical
nuance. This species, along with Plasmodium ovale, places
dormant forms in the liver that may provoke a clinical attack
anywhere between 17 days and up to 3 years following
patency of the primary infection.6 The risk of relapse varies
from<10% to>90% depending upon where acquired, and the
number of relapses ranges from 1 (e.g., Korean strains) to
about 10 (e.g., tropical Asian strains).7 Despite the absence of
prevalent P. vivax across much of Africa due to dominance of
the Duffy negative phenotype (Fig. 1): much of eastern Africa
has endemic vivaxmalaria and travelers to sub-Saharan Africa
certainly acquire vivax malaria,8 and risk may occur on that
continent even where the infection does not appear preva-
lent.9 Drugs used for suppressive chemoprophylaxis kill
Fig. 1 Global map of endemic vivax malaria, reprinted from Ref.3 with permission of the authors and PLoS Neglected Tropical
Diseases.
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parasites after they have matured in the liver and emerged
into the bloodstream (blood schizontocidal). These drugs will
not prevent seeding of the liver with hypnozoites, nor impact
the emergent blood stagesmonths after travel. Inappropriate
management of vivax malaria by underestimating its clinical
threat, the risk of exposure to it, the enduring threat after
travel, or by prescribing ineffective chemoprophylaxis may
result in travelers suffering potentially dangerous clinical
attacks that are difficult to manage and treat.
Treatment provider beware
Difficult chemotherapeutic issues complicate management
of patients with acute vivax malaria. Widespread resistance
to chloroquine occurs5 and there is deep uncertainty
regarding the efficacy and effectiveness of primaquine,10
especially when applied with modern blood schizo-
ntocides.11 The efficacy of primaquine against relapse re-
quires an appropriate partner blood schizontocide, even
when that partner alone has no impact upon hypnozoites,
like chloroquine or quinine.12 In other words, the safety and
efficacy of primaquine when partnered with any given
blood schizontocide(s) may not be presumed – it requires
evidence that is very difficult to obtain and currently very
scarce. Finally, recent studies suggest that a common
mutant genotype of a CYP allele renders primaquine
(combined with chloroquine) ineffective against relapse of
P. vivax.
Clinical aspects of vivax malaria deepen the difficulty of
its management. The benign identity inappropriately
assigned to vivax malaria stemmed in large part from
Fig. 2 Burden of the malarias in Brazil since 1960, reprinted from Ref.22 with permission of the authors and Mem Inst Oswaldo
Cruz. Endemic vivax malaria is less responsive to standard approaches to control and treatment.
Fig. 3 Top graph documents annual citations in published books as a percentage of total literature since 1900 (from http://
books.google.come/ngrams courtesy of Lorenz von Seidlein, Darwin, Australia).
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inherently low numbers of parasites in peripheral blood,
typically at least an order of magnitude lower than those in
patients infected by P. falciparum. Hypothetically, the low-
grade parasitemias may represent only a small proportion
of the threatening biomass: various physical, molecular,
and behavioral characteristics of P. vivax suggest it is
principally an infection of hemopoietic tissues rather than
vascular sinuses.1 If that is proven to be true, a credible
assessment of clinical threat may require examination of
bone marrow aspirate in order to gauge parasite biomass
and its clinical threat in patients. Examination of peripheral
blood films alone may be dangerously misleading.
A recent trial of primaquine against relapse in Indone-
sian soldiers demonstrated a 0.5 mg/kg daily regimen for 14
days as 98% efficacious when combined with dihydroarte-
misinin-piperaquine for radical cure.13 Primaquine therapy
began on day 28 following patency for want of evidence
demonstrating safety of co-administration. This trial
nonetheless offers the first credible evidence for options to
chloroquine-primaquine for radical cure since 1952. Work
promising proof of safety with co-administration is in
progress. Dihydroartemisinin-piperaquine combined with
primaquine should be the preferred option where risk of
resistance to chloroquine occurs, i.e., most endemic zones,
especially Southeast Asia and Oceania.
Poor chemoprophylaxis
The axiomatic superiority of prevention versus cure may be
especially true for vivax malaria. Avoidance of the risks and
difficulties in managing and treating patients with vivax
malaria certainly emphasizes the importance of success in
preventive measures. However, travel medicine doctrine
embraces suppressive chemoprophylactic strategy that is
unreliable against vivax malaria for the logical reasons
already explained e and available evidence demonstrates
this inadequacy. Schwartz and Regev-Yochay14 documented
the relatively high risk of vivax malaria in the months
following travel using suppressive rather than causal pro-
phylaxis among Israeli travelers to eastern Africa: 6%, 53%,
and 52% vivax malaria attack rates with primaquine,
doxycycline, and mefloquine for prophylaxis, respectively,
after more than 3 months following cessation of travel.
Schwartz and colleagues15 described 35%e45% of travelers
suffering malaria developing delayed onset (>2 months
post-travel) malaria, and 90% or more of these were caused
by P. vivax or P. ovale. More to the point, 62%e81% of these
delayed onset cases had been using suppressive chemo-
prophylaxis as prescribed.
Suppressive prophylaxis remains the primary means of
preventing malaria in travelers.16 The risk of relapse in
travelers is supposedly managed by post-travel presump-
tive anti-relapse therapy (PART), i.e., a daily dose of
0.5 mg/kg primaquine for 14 days.17 However, as
explained by Freedman,18 “.presumptive antirelapse
therapy is used infrequently in practice and only in pa-
tients with the most obvious and prolonged exposure to
infective mosquitoes”. One agency advises, “.routine
use of primaquine for prophylaxis [post-travel PART] is not
recommended.”.19 The US CDC advises16 on post-travel
PART, “Presumptive antirelapse therapy is generally
indicated only for people who have had prolonged expo-
sure in malaria endemic areas (such as missionaries or
volunteers).” The consequences of these practices include
several hundred cases of delayed onset post-travel vivax
malaria each year in the United States alone.14,18 In 2010
in the USA, 319 people were diagnosed with P. vivax, with
41% of those occurring more than a month after return
from travel.20 Further, among the 946 patients known to
have been hospitalized with a primary diagnosis of malaria
in the USA, 95 had a diagnosis of P. vivax and 20% of those
patients (n Z 19) suffered severe illness20 e roughly the
same rate of severe illness occurring in many hospitals in
endemic zones.1 Does avoidance of the cost, inconve-
nience, and risk of post-travel PART merit these infections
collateral to demonstrably poor chemoprophylaxis strat-
egy? Few providers today, understanding vivax malaria as
capable of a pernicious course, as it certainly is in trav-
elers [see listing of case reports in reference #1], would
consider permitting relapse in their patients an acceptable
option.
Unfortunately, post-travel PART comes with more than
cost, inconvenience and risk of toxicity pitfalls e there is no
evidence of safety or efficacy when used following sup-
pressive prophylaxis (with the certain exception of chloro-
quine and the possible exception of mefloquine). As
explained elsewhere, the efficacy of primaquine against
hypnozoites requires an appropriate partner drug in radical
cure.11,12 The evidence for this, developed during the
pivotal clinical trials of primaquine 65 years ago, became
forgotten and mostly irrelevant in practice because the
chloroquine partner for primaquine was the drug of choice
in both chemoprophylaxis and treatment. Primaquine kills
hypnozoites when partnered with chloroquine for either
indication. However, the efficacy of primaquine when used
after other suppressive chemoprophylactic drugs like
doxycycline or atovaquone/proguanil has not been
demonstrated. Indeed, good efficacy for primaquine may
be doubtful when partnered with these relatively rapidly
excreted drugs. When Alving et al.21 gave primaquine
following rather than currently with daily quinine for
therapy of acute vivax malaria, 15 of 19 versus 2 of 19
subjects, respectively, suffered relapse. Similar findings,
reported before and after this report, all point to the same
conclusion: primaquine requires an appropriate companion
drug to achieve good efficacy at doses normally considered
therapeutic.11,12
Available evidence strongly suggests that post-travel
PART administered following travel using the most widely
prescribed agents of malaria chemoprophylaxis may have
no efficacy against relapse of P. vivax. This possibility
taken with the general reluctance to even recommend
the treatment, suggests that suppressive chemoprophy-
laxis may be reasonably expected to routinely fail against
vivax malaria. The report from Schwartz and colleagues15
from nine years ago came with this conclusion, “Agents
that act on the liver phase of malaria parasites are
needed for more effective prevention of malaria in
travelers.” The primary aim of this commentary in this
especially relevant issue of Travel Medicine & Infectious
Diseases is to revisit and emphasize this point against a
backdrop of dangerous and difficult to manage and treat
vivax malaria.
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Primaquine for primary prophylaxis
The good safety, tolerability and efficacy of daily prima-
quine for primary causal prophylaxis have been demon-
strated in subjects considered good candidates for the drug
(G6PD-normal, not pregnant).14,22,23 This may seem to
contradict the already explained reliance of primaquine on
appropriate partner drugs to prevent relapse, but it does
not e daily primaquine during exposure to infection kills
early developmental stages of the parasite in the liver
rather than mature hypnozoites. The necessity of daily
dosing of primaquine thus begins with travel and ends a few
days following exposure to risk (evidence supports 5 days,
but 2 or 3 days may suffice). The returned traveler may be
assumed to be free of hypnozoites.
Although primaquine is certainly dangerous to pregnant
women and patients with G6PD deficiency, it proved
remarkably safe and well tolerated in other patients
consuming 0.5 mg/kg daily for 16e50 weeks. Among non-
pregnant and G6PD-normal subjects taking the recom-
mended daily adult dose of 30 mg with a snack for as long as
50 weeks in a double-blinded and placebo-controlled trial,
safety and tolerability was comparable to placebo.24 The
well-known and rarely symptomatic met-hemoglobinemia
of primaquine therapy (averaging about 6% met-
hemoglobin after several days dosing) was not exacer-
bated with prolonged dosing and returned to normal levels
within 2 weeks of cessation.24,25 Other studies reported
similarly good safety and tolerability.26,27 One study in
Colombian soldiers in the field reported discontinuation of
primaquine prophylaxis in 3 of 122 subjects due to severe
gastrointestinal distress; six others had mild to moderate
distress.28
Reluctance to use primaquine for primary
prophylaxis
Apart from the caveat of contraindications for pregnant
women and patients with G6PD deficiency, daily prima-
quine during travel seems the ideal chemoprophylactic
solution for most of the endemic world. So why is prima-
quine not more widely recommended and used? Several
factors must be considered in striving to answer this
important question: 1) the long dominance of suppressive
chemoprophylaxis in travel medicine doctrine; 2) the
perception of vivax malaria as harmless; and 3) primaquine
not having a registered therapeutic indication for primary
prophylaxis.
As in many other areas of medicine and public
health,29,30 the presumed harmlessness of vivax malaria
relegated it to neglect in travel medicine. The virtually
exclusive monopoly on chemoprophylaxis by suppressive
drugs effective against falciparum malaria dates to the
licensing of chloroquine in 1946. Risk of delayed onset vivax
malaria after travel with suppressive prophylaxis seemed
preferable to the inconvenience and complexity of post-
travel PART with primaquine.18,19 Certainly the availabil-
ity of good evidence of safety and efficacy of primaquine
for primary prophylaxis for over a decade has yet to prompt
real change in chemoprophylaxis strategy. Suppressive
prophylactic drugs remain today, according to most
authorities, first-, second-, and third-line options for
chemoprophylaxis in travelers.16e18 Primaquine primary
prophylaxis is either a last option, listed as a footnote, or
not mentioned.19 One cannot know precisely what the
makers of such recommendations weighed, but clinically
inconsequential vivax malaria would appear to have been a
key consideration to strategies favoring suppressive
chemoprophylaxis with post-travel PART scarcely recom-
mended or not at all.
The travel medicine community has been reluctant to
prescribe primaquine for primary prophylaxis as a conse-
quence of off-label use liability. Fifteen years ago efforts
by the U.S. Department of Defense to have primary pro-
phylaxis added to the primaquine label as an approved
indication ended in frustration e no stakeholder was willing
to bear the cost of doing so. Acknowledging the clinical
threat of vivax malaria and the inadequacy of suppressive
prophylaxis against it should spark renewed efforts to see
the label for primaquine include an indication for primary
prophylaxis. The travel medicine community, being the
primary stakeholder in this issue, should engage in advo-
cacy for regulatory action on this vitally important drug
that brings sanctioned use as primary prophylaxis.
The view of primaquine casual prophylaxis as unsuitable
for travel to Africa, aired in some travel medicine circles,
may have created the false impression that it is ineffective
against P. falciparum. The basis of that view would likely
have been the presumably low risk of vivax malaria rather
than a high risk of falciparum malaria. Primaquine exhibits
relatively poor blood schizontocidal activity against P. fal-
ciparum, but this has no bearing on its activity in causal
prophylaxis e killing early liver stages precludes the rele-
vance of blood schizontocidal activity in chemoprophylaxis.
Risk of “breakthrough” parasitemias with primaquine pro-
phylaxis, as occur with suppressive prophylaxis, being more
likely to advance more quickly to threatening illness is
speculative and not supported by available data in patients.
Atovaquone-proguanil has causal prophylactic activity
against P. falciparum, and this is the basis of the recom-
mendation to consume it for 7 days rather than the usual 28
days for suppressive chemoprophylaxis.30 However, this
activity against P. vivax or P. ovale has not been demon-
strated31 and at least several cases suggest atovaquone-
proguanil prophylaxis does not prevent formation of
hypnozoites.32e35
Due diligence
Today and for the foreseeable future, primaquine is the
only widely available drug offering good evidence of safety,
tolerability, and efficacy against primary infections of both
P. vivax and P. falciparum during exposure, and against
relapse of P. vivax in the months following exposure. This
evidence, weighed against that showing unequivocal poor
performance of suppressive prophylactic drugs against
delayed onset vivax malaria in travelers e along with evi-
dence of risk of vivax malaria across much of the globe e
raises an obvious and important question for the travel
medicine community: Is recommending and prescribing
suppressive prophylaxis for any traveler the reckless option
to primaquine causal prophylaxis?
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